Stefan Arver

Stefan Arver

Auto-generated profile, based on publicly available information

Stefan Arver

Department of Medicine/Huddinge Karolinska Institutet and ANOVA, Karolinska University Hospital, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2011 in Diabetes Care
Verified
Journal Article
Open access
TJThomas Hugh Jones
Thomas Hugh Jones
SAStefan Arver
Stefan Arver
HBHermann M. Behre
Hermann M. Behre
JBJacques Buvat
Jacques Buvat
EMEric Meuleman
Eric Meuleman
TITIMES2 Investigators
TIMES2 Investigators
OBJECTIVE: This study evaluated the effects of testosterone replacement therapy (TRT) on insulin resistance, cardiovascular risk factors, and symptoms in hypogonadal men with type 2 diabetes and/or metabolic syndrome (MetS). RESEARCH DESIGN AND METHODS: The efficacy, safety, and tolerability of a novel transdermal 2% testosterone gel was evaluated over 12 months in 220 hypogonadal men with type 2 diabetes and/or MetS in a multicenter, prospective, randomized, double-blind, placebo-controlled study. The primary outcome was mean change from baseline in homeostasis model assessment of insulin resistance (HOMA-IR). Secondary outcomes were measures of body composition, glycemic control, lipids, and sexual function. Efficacy results focused primarily on months 0−6 (phase 1; no changes in medication allowed). Medication changes were allowed in phase 2 (months 6−12). RESULTS: TRT reduced HOMA-IR in the overall population by 15.2% at 6 months (P = 0.018) and 16.4% at 12 months (P = 0.006). In type 2 diabetic patients, glycemic control was significantly better in the TRT group than the placebo group at month 9 (HbA1c: treatment difference, −0.446%; P = 0.035). Improvements in total and LDL cholesterol, lipoprotein a (Lpa), body composition, libido, and sexual function occurred in selected patient groups. There were no significant differences between groups in the frequencies of adverse events (AEs) or serious AEs. The majority of AEs (>95%) were mild or moderate. CONCLUSIONS: Over a 6-month period, transdermal TRT was associated with beneficial effects on insulin resistance, total and LDL-cholesterol, Lpa, and sexual health in hypogonadal men with type 2 diabetes and/or MetS.

2 January 2015 in The Aging Male
Verified
Journal Article
Open access
BLBruno Lunenfeld
Bruno Lunenfeld
GMGeorge Mskhalaya
George Mskhalaya
MZMichael Zitzmann
Michael Zitzmann
SAStefan Arver
Stefan Arver
SKSvetlana Kalinchenko
Svetlana Kalinchenko
AMAbraham Morgentaler
Abraham Morgentaler
Hypogonadism or Testosterone Deficiency (TD) in adult men as defined by low levels of serum testosterone accompanied by characteristic symptoms and/or signs as detailed further on can be found in long-recognized clinical entities such as Klinefelter syndrome, Kallmann syndrome, pituitary or testicular disorders, as well as in men with idiopathic, metabolic or iatrogenic conditions that result in testosterone deficiency. These recommendations do not encompass the full range of pathologies leading to hypogonadism (testosterone deficiency), but instead focus on the clinical spectrum of hypogonadism related to metabolic and idiopathic disorders that contribute to the majority of cases that occur in adult men.

29 May 2014 in Archives of Sexual Behavior
Verified
Journal Article
Closed access
PDF file
CDCecilia Dhejne
Cecilia Dhejne
KÖKatarina Öberg
Katarina Öberg
SAStefan Arver
Stefan Arver
MLMikael Landén
Mikael Landén

1 March 2009 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
JCJuan Jesu[Combining Acute Accent]S Carrero
Juan Jesu[Combining Acute Accent]S Carrero
AQAbdul Rashid Qureshi
Abdul Rashid Qureshi
PPPaolo Parini
Paolo Parini
SAStefan Arver
Stefan Arver
BLBengt Lindholm
Bengt Lindholm
PSPeter Stenvinkel
Peter Stenvinkel
Men treated with hemodialysis (HD) have a very poor prognosis and an elevated risk of premature cardiovascular disease (CVD). In the general population, associations between low testosterone concentrations and cardiovascular risk have been suggested. We performed a prospective observational study involving a well characterized cohort of 126 men treated with HD to examine the relationship between testosterone concentration and subsequent mortality during a mean follow-up period of 41 mo. Independent of age, serum creatinine, and sexual hormone binding globulin (SHBG), testosterone levels inversely and strongly associated with the inflammatory markers IL-6 and CRP. Patients with a clinical history of CVD had significantly lower testosterone levels. During follow up, 65 deaths occurred, 58% of which were a result of CVD. Men with testosterone values in the lowest tertile had increased all-cause and CVD mortality (crude hazard ratios [HRs] 2.03 [95% CI 1.24 to 3.31] and 3.19 [1.49 to 6.83], respectively), which persisted after adjustment for age, SHBG, previous CVD, diabetes, ACEi/ARB treatment, albumin, and inflammatory markers, but was lost after adjustment for creatinine. In summary, among men treated with HD, testosterone concentrations inversely correlate with all-cause and CVD-related mortality, as well as with markers of inflammation. Hypogonadism may be an additional treatable risk factor for patients with chronic kidney disease.

11 July 2010 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
JCJuan Jesús Carrero
Juan Jesús Carrero
AQAbdul Rashid Qureshi
Abdul Rashid Qureshi
ANAyumu Nakashima
Ayumu Nakashima
SAStefan Arver
Stefan Arver
PPPaolo Parini
Paolo Parini
PSPeter Stenvinkel
Peter Stenvinkel
Background. Abnormally low serum testosterone levels were recently associated with an increased mortality risk in male dialysis patients. However, the prevalence of testosterone deficiency in end-stage renal disease (ESRD) is not well defined. We hereby explore the prevalence and correlates of clinical testosterone deficiency in a large cohort of ESRD male patients. Methods. Two hundred and sixty ESRD men [median age 59 (25th–75th percentile 48–67) years] were included. Testosterone concentration and testosterone deficiency (14 nmol/L). Testosterone was strongly and inversely correlated to inflammatory markers (CRP, IL-6 and fibrinogen), even after correction for age and sex hormone-binding globulin. In a crude spline curve, low testosterone concentrations were associated with worse outcome. A clinical condition of testosterone deficiency was independently associated with cardiovascular co-morbidity [odds ratio (OR) 2.51; 95% confidence interval (CI) 1.32–4.76] and death (OR 2.00; 95% CI 1.01–3.97) in logistic regression analyses. Conclusions. Testosterone deficiency is a common finding among male ESRD patients, and it is independently associated with inflammation, cardiovascular co-morbidity and outcome. Future studies are needed to determine the potential adverse effects of male hypogonadism in ESRD and the possibility of improving risk profile, quality of life, and ultimately outcome with testosterone supplementation in these patients.

1 June 1996 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
AHAr Helgason
Ar Helgason
JAJ Adolfsson
J Adolfsson
PDP Dickman
P Dickman
MFM Fredrikson
M Fredrikson
SAS Arver
S Arver
GSGunnar Steineck
Gunnar Steineck
The objective was to investigate how prostate cancer and its treatment affects sexual, urinary and bowel functions and to what extent eventual complications cause distress. A questionnaire was sent to 431 men aged 50-80 years with prostate cancer diagnosed in 1992 in the Stockholm area (Sweden) and 435 randomly selected men with a similar age distribution. Sexual function, as compared with their youth, was diminished in a majority of all men. The prostate cancer patients were, however, more likely to report low frequency and/or intensity in all aspects of sexual function. A majority of the men were distressed by a waning sexual capacity. The proportion of men with prostate cancer who were severely distressed owing to a decline in sexual function was larger than in the reference group. The willingness to trade off an intact sexual function for long-term survival varied considerably among the men in the reference group. Urinary and bowel symptoms were less common than a waning sexual function in both groups, and few appeared to be severely distressed by urinary or bowel symptoms. A decline in sexual functions was the most common cause of disease-specific distress in men with prostate cancer.